Enanta Pharmaceuticals, Inc. (FRA:9EP)
Germany · Delayed Price · Currency is EUR | Market Cap | 302.74M +16.1% |
| Revenue (ttm) | 57.12M +0.7% |
| Net Income | -55.35M |
| EPS | -2.08 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2 |
| Open | 10.20 |
| Previous Close | 10.20 |
| Day's Range | 9.30 - 10.30 |
| 52-Week Range | 8.65 - 14.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 16, 2026 |
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urtica... [Read more]
Financial Performance
In fiscal year 2025, Enanta Pharmaceuticals's revenue was $65.32 million, a decrease of -3.42% compared to the previous year's $67.64 million. Losses were -$81.89 million, -29.43% less than in 2024.
Financial numbers in USD Financial StatementsNews
Enanta announces first patient dosed in Resolve Phase 2b/3 trial
Enanta (ENTA) Pharmaceuticals announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical trial of zelicapavir in adults at high risk of severe outcomes from…
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunol...
Enanta Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Key RSV and immunology programs are advancing, with zelicapavir moving to a single phase III trial in high-risk adults and a pediatric study underway. The pipeline includes novel KIT, STAT6, and MRGPRX2 inhibitors, with strong financial resources and plans for commercial partnerships.
Enanta Pharmaceuticals Transcript: 2026 Global Healthcare Conference
The company is advancing a pipeline of wholly owned assets, focusing on RSV and I&I. Key RSV studies target high-risk pediatric and elderly populations, with new clinical tools and single registration study designs. I&I programs include oral KIT and STAT6 inhibitors, and a novel MRGPRX2 antagonist, supported by strong financials and ongoing royalty streams.
Enanta Pharmaceuticals to Participate in September Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals Earnings release: Q3 2026
Enanta Pharmaceuticals released its Q3 2026 earnings on August 10, 2026, summarizing the period's financial results.
Enanta Pharmaceuticals Quarterly report: Q3 2026
Enanta Pharmaceuticals has published its Q3 2026 quarterly earnings report on August 10, 2026.
Enanta announces European Commission approval of Maviret
Enanta (ENTA) announced that the European Commission has approved Maviret, an oral pangenotypic direct-acting antiviral therapy, for the treatment of acute HCV infection without cirrhosis or with comp...
Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta to advance zelicapavir into registrational Phase 2b/3 clinical trial
Enanta (ENTA) Pharmaceuticals is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes from RSV infection after a successful End-of-Phase 2 me...
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The discussion highlighted progress in RSV drug development, with strong efficacy signals and ongoing FDA engagement for a novel registration path. Strategic flexibility includes both internal and partnership-driven trial execution, while preclinical data support robust target engagement for pipeline assets.
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals Earnings release: Q2 2026
Enanta Pharmaceuticals released its Q2 2026 earnings on May 11, 2026, summarizing the period's financial results.
Enanta Pharmaceuticals Quarterly report: Q2 2026
Enanta Pharmaceuticals has published its Q2 2026 quarterly earnings report on May 11, 2026.
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta announces first participant dosed in Phase 1 trial of EDP-978
Enanta (ENTA) Pharmaceuticals announced that the first participant has been dosed in a Phase 1 clinical trial of EDP-978, an oral, once-daily KIT inhibitor in development for urticaria and other…
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
Enanta initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Seema Sheoran initiated coverage of Enanta (ENTA) with a Buy rating and $20 price target
Enanta Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
The company is advancing two RSV drug candidates, with zelicapavir showing strong Phase II efficacy and EDP-323 demonstrating rapid viral suppression. Three immunology programs are progressing, with KIT and STAT6 targeting major inflammatory diseases and all I&I efforts funded through early clinical stages.
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...